Arch Biopartners Inc

Arch Biopartners Inc. a biotechnology company engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs liver and kidneys which results in organ damage or failure including in the case of sepsis and COVID-19. The company also develops AB569 an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections primarily as a topical treatment for wounds. In addition it develops Borg a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto Canada.